Roisin M Lonergan

Summary

Affiliation: St Vincent's University Hospital
Country: Ireland

Publications

  1. doi request reprint Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype
    R Lonergan
    Department of Neurology, St Vincent s University Hospital, Elm Park, Dublin 4, Ireland
    J Neurol Neurosurg Psychiatry 82:317-22. 2011
  2. doi request reprint Reactivation of BK polyomavirus in patients with multiple sclerosis receiving natalizumab therapy
    Roisin M Lonergan
    Department of Neurology, St Vincent s University Hospital, Elm Park, Dublin, Ireland
    J Neurovirol 15:351-9. 2009
  3. doi request reprint Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?
    Roisin Lonergan
    St Vincent s University Hospital, Neurology, Dublin, Republic of Ireland
    Mult Scler 15:1528-31. 2009

Detail Information

Publications3

  1. doi request reprint Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype
    R Lonergan
    Department of Neurology, St Vincent s University Hospital, Elm Park, Dublin 4, Ireland
    J Neurol Neurosurg Psychiatry 82:317-22. 2011
    ..The hypothesis that, in Ireland, MS prevalence is increasing and that north-south differences relate to variation in serum 25-hydroxyvitamin D (25(OH)D) levels was tested in this study...
  2. doi request reprint Reactivation of BK polyomavirus in patients with multiple sclerosis receiving natalizumab therapy
    Roisin M Lonergan
    Department of Neurology, St Vincent s University Hospital, Elm Park, Dublin, Ireland
    J Neurovirol 15:351-9. 2009
    ..We propose regular monitoring for BK reactivation or at least for evidence of renal dysfunction in patients receiving natalizumab...
  3. doi request reprint Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?
    Roisin Lonergan
    St Vincent s University Hospital, Neurology, Dublin, Republic of Ireland
    Mult Scler 15:1528-31. 2009
    ..The costs of disease-modifying therapies in this group (>170,000 euro yearly) could be re-directed towards development of neurology services to optimize their management...